Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis: Results from a randomized double blind placebo controlled trial

Table 3 Comparison of clinical remission, improvement in Ulcerative Colitis Disease Activity Index and Baron’s score, and mucosal healing at 8^th week between two randomized groups

	Curcumin group	Placebo group	OR (95%CI)	P value
Clinical remission
PP1	9/16 (56.25%)	9/25 (36%)	2.28 (0.634-8.264)	0.202
ITT2	9/29 (31.03%)	9/33 (27.27%)	1.20 (0.40-3.60)	0.745
UCDAI improvement by ≥ 3
PP	6/16 (37.5%)	12/25 (48%)	0.65 (0.18-2.34)	0.509
ITT	6/29 (20.69%)	12/33 (36.36%)	0.46 (0.14-1.43)	0.175
Mucosal healing1
PP	10/16 (62.5%)	10/25 (40%)	2.50 (0.69-9.09)	0.16
ITT	10/29 (34.5%)	10/33 (30.3%)	1.21 (0.4 – 3.5)	0.72

¹Healing defined by either endoscopically normal mucosa or only mucosal granularity. Any ulceration or friability was taken as non-healed mucosa. PP: Per-protocol; ITT: Intention to treat; UCDAI: Ulcerative Colitis Disease Activity Index.